Search Results - "PICCHIO, Gaston"
-
1
Telaprevir for Retreatment of HCV Infection
Published in The New England journal of medicine (23-06-2011)“…In patients with HCV infection who did not have a sustained response to peginterferon plus ribavirin, the addition of telaprevir to this combination therapy…”
Get full text
Journal Article -
2
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Published in The Lancet (British edition) (15-11-2014)“…Summary Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and…”
Get full text
Journal Article -
3
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
Published in Antimicrobial Agents and Chemotherapy (01-02-2010)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
4
Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine
Published in Journal of acquired immune deficiency syndromes (1999) (01-09-2011)“…The contribution of E138 mutations to etravirine resistance was investigated. Amino acids at position E138 after failure with etravirine in DUET were A (n =…”
Get full text
Journal Article -
5
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
Published in Clinical infectious diseases (15-07-2013)“…Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact…”
Get full text
Journal Article -
6
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Published in Journal of Virology (01-02-2013)“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
7
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Published in Journal of antimicrobial chemotherapy (01-02-2010)“…Promising results have been observed with an investigational drug class for hepatitis C (HCV), the specifically targeted antiviral therapies for hepatitis C…”
Get full text
Journal Article -
8
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Published in AIDS (London) (13-11-2009)“…To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, over…”
Get full text
Journal Article Web Resource -
9
The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness
Published in Journal of acquired immune deficiency syndromes (1999) (01-01-2012)“…The registrational phase III clinical trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two…”
Get full text
Journal Article -
10
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
Published in PloS one (12-04-2012)“…In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased…”
Get full text
Journal Article -
11
Telaprevir for Retreatment of HCV Infection
Published in The New England journal of medicine (23-06-2011)Get full text
Journal Article -
12
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine
Published in Antiviral therapy (01-01-2014)“…The prevalence of rilpivirine resistance-associated mutations (RAMs) in the USA, and their effect on phenotypic susceptibility to rilpivirine and etravirine,…”
Get more information
Journal Article -
13
Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection
Published in Journal of Virology (01-02-2003)“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
14
Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3-4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study
Published in The Journal of infectious diseases (15-12-2014)“…Background. Population sequencing (PS) has shown that telaprevir-resistant variants are not typically detectable at baseline (prevalence, ≤5% of patients), and…”
Get full text
Journal Article -
15
Resistance profile of darunavir: combined 24-week results from the POWER trials
Published in AIDS research and human retroviruses (01-03-2008)“…The resistance profile of darunavir (TMC114) in treatment-experienced patients was explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended…”
Get more information
Journal Article -
16
Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial
Published in The Journal of infectious diseases (15-09-2013)“…Background. This partially blinded, randomized, phase 2a C210 study evaluated the antiviral activity of telaprevir-based regimens in treatment-naive patients…”
Get full text
Journal Article -
17
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE
Published in Journal of medical virology (01-05-2016)“…Minority variants (1.0–25.0%) were evaluated by deep sequencing (DS) at baseline and virological failure (VF) in a selection of antiretroviral treatment‐naïve,…”
Get full text
Journal Article -
18
Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy
Published in Journal of Clinical Microbiology (01-07-2003)“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
19
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B
Published in Hepatology communications (01-12-2022)“…AB‐506 is a potent, pan‐genotypic small molecule capsid inhibitor that inhibits hepatitis B virus (HBV) pregenomic RNA encapsidation. We assessed the safety,…”
Get full text
Journal Article -
20
TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors
Published in Antimicrobial Agents and Chemotherapy (01-12-2011)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article